Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Px-102. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 20/20 | 1.00 |
| ▸ | FXR2 | P51116 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Px-102 SCHEMBL29366746 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL29823470 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087855 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087854 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL19633868 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL24662891 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087850 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087856 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL29709582 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL12098287 | 0.95 | NR1H4 (0.91) | NR1H4FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110404073-B | Methods and pharmaceutical compositions for treating hepatitis B virus infection | 国家医疗保健研究所 | 2022-08-16 | — | — | CN | claimed |
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | claimed |
| EP-2467366-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-12 | — | — | EP | claimed |
| WO-2013037482-A1 | FARNESOID X RECEPTOR AGONISTS FOR CANCER TREATMENT AND PREVENTION | PHENEX PHARMACEUTICALS AG (DE) | 2013-03-21 | — | — | WO | claimed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | claimed |
| EP-2467366-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2012-06-27 | — | — | EP | claimed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | claimed |
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3650449-B1 | FXR RECEPTOR AGONIST | XUANZHU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20220323414-A1 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | METACRINE, INC. | 2022-10-13 | — | — | US | disclosed |
| CN-110404073-B | Methods and pharmaceutical compositions for treating hepatitis B virus infection | 国家医疗保健研究所 | 2022-08-16 | — | — | CN | disclosed |
| US-11352358-B2 | FXR agonist | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20220047553-A1 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | METACRINE, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-2545964-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2467366-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323414-A1 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | NR1H4, FXR1, NR1H2 | NR1H4 1/4885FXR2 7/4885 |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FXR2 5/4885 |
| US-11352358-B2 | FXR agonist | NR1H4, FXR1, NR1H3 | NR1H4 1/4885FXR2 6/4885 |
| US-20220047553-A1 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | NR1H4, FXR1, NR1H2 | NR1H4 1/4885FXR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.